0001104659-24-008418.txt : 20240130 0001104659-24-008418.hdr.sgml : 20240130 20240130203855 ACCESSION NUMBER: 0001104659-24-008418 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240126 FILED AS OF DATE: 20240130 DATE AS OF CHANGE: 20240130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LAWLOR AUGUSTINE CENTRAL INDEX KEY: 0001262327 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37990 FILM NUMBER: 24580320 MAIL ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 301 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LEAP THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001509745 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 274412575 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 47 THORNDIKE STREET STREET 2: SUITE B1-1 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617 252 4343 MAIL ADDRESS: STREET 1: 47 THORNDIKE STREET STREET 2: SUITE B1-1 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Dekkun Corp DATE OF NAME CHANGE: 20110107 4 1 tm244628-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-01-26 0 0001509745 LEAP THERAPEUTICS, INC. LPTX 0001262327 LAWLOR AUGUSTINE C/O LEAP THERAPEUTICS, INC. 47 THORNDIKE STREET SUITE B1-1 CAMBRIDGE MA 02141 0 1 0 0 Chief Operating Officer 0 Common Stock 2024-01-26 4 M 0 5000 A 5086 D Common Stock 261840 I HCV VIII Liquidating Trust Common Stock 414480 I By HealthCare Ventures IX, L.P. Restricted Stock Units 2024-01-26 4 M 0 5000 0 D Common Stock 5000 0 D Restricted Stock Units convert into common stock on a one-for-one basis. The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023. The reporting person is the Manager of HCV VIII Liquidating Trust and maintains shared voting and dispositive power over the shares held by HCV VIII Liquidating Trust. The reporting person disclaims beneficial ownership of the shares held by HCV VIII Liquidating Trust except to the extent of his proportionate pecuniary interest therein. The reporting person is a Managing Director of HealthCare Partners IX, LLC which is the General Partner of HealthCare Partners IX, L.P., which is the General Partner of HealthCare Ventures IX, L.P. The reporting person beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HealthCare Ventures IX, L.P. and disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein. On January 26, 2021, the reporting person was granted 5,000 Restricted Stock Units, vesting on January 26, 2024 or upon a change of control, whichever is earlier, provided that the grantee continues to be employed by, or provides service to the Company from the grant date to the vesting date of the Restricted Stock Units. At such time as the Restricted Stock Units vest, one share of Common Stock shall be issued automatically in settlement of each Restricted Stock Unit. /s/ Douglas E. Onsi, as attorney-in-fact for Augustine Lawlor 2024-01-30